← All diseases

Disease Atlas / Disease detail

Creutzfeldt-Jakob Disease (CJD)

An educational draft summarizing the identity, clinical course, framework for diagnosis and management, and precautions for interpreting evidence of CJD

Creutzfeldt Jacob disease · CJD · CJD (Creutzfeldt Jakob disease) · Creutzfeldt Jakob Disease · Creutzfeldt-Jacob disease · Jakob-Creutzfeldt disease · classic Creutzfeldt-Jakob disease

MONDO:0005357Public QA completeSource-bound · 4

Disease at a glance

Start with the essentials, then explore the patient and research views.

Public revision · 66cc01f03e16

Disease category
Creutzfeldt-Jakob disease (CJD) is a rare and rapidly progressive neurodegenerative brain disorder.
Core mechanism
CJD is classified into sporadic, genetic, and acquired forms; the acquired form can rarely occur following medical procedures involving infected tissue.
Main causes/related factors
It is understood that abnormally folded prion proteins induce the misfolding of normal proteins and cause neuronal damage.
Representative patterns
Typical manifestations include rapidly progressive memory loss, behavioral changes, visual disturbances, and decreased muscle coordination.
Individual differences
Most cases occur without a clear cause, but in familial forms, family history is significant, and specific exposure to medical tissues may be associated with acquired risk.
Diagnosis
Symptoms usually begin in old age and rapidly progress to dementia and coma, with most patients dying within one year.
Management
The diagnosis follows a broad framework that synthesizes medical history and neurological examination with MRI, EEG, cerebrospinal fluid testing, etc., and confirms via brain tissue pathology if necessary.
Treatment/Research Status
It is difficult to confirm with a single test alone, and since similar rapidly progressive dementias or metabolic/inflammatory diseases must be excluded, integrated interpretation by a specialist is required.
Read Evidence
The center of management is multidisciplinary support, including safety, communication, nutrition, symptom control, prevention of complications, and care/palliative care for the patient and family.
Key Precautions
In current clinical management, the focus is on supportive care and symptom relief rather than standard treatments that definitively stop disease progression.

For patients and families

A structured guide for understanding the disease and preparing for clinical conversations.

At a Glance

Creutzfeldt-Jakob disease (CJD) is a rare and rapidly progressive neurodegenerative brain disorder.

Typical manifestations include rapidly progressive memory loss, behavioral changes, visual disturbances, and decreased muscle coordination.

How the disease works

CJD is classified into sporadic, genetic, and acquired forms; the acquired form can rarely occur following medical procedures involving infected tissue.

It is understood that abnormally folded prion proteins induce the misfolding of normal proteins and cause neuronal damage.

Variations in presentation among individuals

Most cases occur without a clear cause, but in familial forms, family history is significant, and specific exposure to medical tissues may be associated with acquired risk.

The broad framework of diagnosis and management

Symptoms usually begin in old age and rapidly progress to dementia and coma, with most patients dying within one year.

The diagnosis follows a broad framework that synthesizes medical history and neurological examination with MRI, EEG, cerebrospinal fluid testing, etc., and confirms via brain tissue pathology if necessary.

Current status of treatment

It is difficult to confirm with a single test alone, and since similar rapidly progressive dementias or metabolic/inflammatory diseases must be excluded, integrated interpretation by a specialist is required.

The center of management is multidisciplinary support, including safety, communication, nutrition, symptom control, prevention of complications, and care/palliative care for the patient and family.

In current clinical management, the focus is on supportive care and symptom relief rather than standard treatments that definitively stop disease progression.

How to read clinical trials

ClinicalTrials.gov contains a record of Platelet-Rich Plasma Injection as an interventional study associated with CJD, but the fact of registration or completion alone cannot be used to determine efficacy, approval, or status as standard care.

Points to verify during clinical consultations

In clinical practice, it is important to identify the timing of symptom onset and rate of progression, family history, past medical procedures and tissue exposure, medications taken, the significance of test results, and care goals.

Medical Guidance

This material is for educational purposes and is not intended as a guide for individual diagnosis or treatment. Consult with medical professionals regarding the interpretation of symptoms or test results.

Evidence and sources

A trial registry status does not establish efficacy or regulatory approval.